IL-15 and STAT3 Inhibition for Bone and Soft Tissue Sarcoma Cancer Therapy

Abstract

Researchers at the University of California, Davis have developed a combinatorial cancer treatment that enhances IL-15 mediated immune activation while inhibiting STAT3 to suppress myeloid-derived immune suppression in bone and soft tissue sarcomas.

Full Description

This technology involves a novel therapeutic approach combining IL-15 pathway activation with STAT3 inhibition to treat bone and soft tissue sarcomas. IL-15 typically stimulates cytotoxic lymphocytes to promote tumor killing; however, it paradoxically activates STAT3 signaling in myeloid-derived suppressor cells (MDSCs), enhancing their immunosuppressive functions and limiting IL-15’s anticancer efficacy. By selectively inhibiting STAT3, this method uncouples IL-15's beneficial immune effects from its undesirable pro-tumor effects, restoring robust antitumor immunity. The approach employs IL-15 activating agents such as recombinant proteins or superagonists alongside STAT3 inhibitors including small molecules or oligonucleotides, optionally combined with NF-κB inhibitors to further suppress MDSCs.

Applications

• Therapeutic treatment of bone sarcomas and soft tissue sarcomas in humans. 
• Development of novel immunotherapy drugs combining IL-15 agonists and STAT3 inhibitors. 
• Adjunct therapy alongside chemotherapy, surgery, or other cancer treatments. 
• Veterinary cancer immunotherapy applications, especially for canine osteosarcoma. 
• Pharmaceutical development of combination biologics and targeted small molecule inhibitors for immuno-oncology.

Features/Benefits

• Activates NK cells and CD8+ T cells to strengthen antitumor immunity via IL‑15. 
• Inhibits STAT3 signaling in MDSCs to reduce IL‑15–associated immunosuppression. 
• Improves treatment responses in bone and soft tissue sarcomas by limiting immune escape in the tumor microenvironment. 
• Enables flexible development and delivery by supporting multiple IL‑15 agonist types and STAT3-inhibitor formats (e.g., small molecules, peptides, siRNAs). 
• Supports combination regimens by pairing with NF‑κB inhibitors to further suppress MDSC accumulation and function. 
• Prevents IL‑15 from driving pro-tumor MDSC activation, thereby avoiding paradoxical pro-tumor effects. Overcomes STAT3-mediated myeloid suppression to reduce immunotherapy resistance. 
• Targets tumor-promoting immune cells to relieve suppression without impairing cytotoxic lymphocytes.

Patent Status

Patent Pending